Curcumin (CUR) has a bright future in the treatment of
cancer as a natural active ingredient with great potential. However,
curcumin has a low solubility, which limits its clinical application. In this study,
IRMOF-10 was created by the direct addition of
triethylamine, CUR was loaded into
IRMOF-10 using the
solvent adsorption method, and the two were characterized using a scanning electron microscope (SEM), X-ray diffraction (XRD), dynamic light scattering (DLS), Fourier transform infrared spectroscopy (FTIR), thermogravimetric analysis (TG) methods, and Brunauer-Emmett-Teller (BET) analysis. We also used the MTT method,
4',6-diamidino-2-phenylindole (
DAPI) staining, the
annexin V/PI method, cellular uptake,
reactive oxygen species (ROS), and the mitochondrial membrane potential (
MMP) to perform a safety analysis and anticancer activity study of
IRMOF-10 and CUR@IRMOF-10 on HepG2 cells. Our results showed that CUR@IRMOF-10 had a CUR load of 63.96%, with an obvious slow-release phenomenon. The CUR levels released under different conditions at 60 h were 33.58% (pH 7.4) and 31.86% (pH 5.5). Cell experiments proved that
IRMOF-10 was biologically safe and could promote
curcumin entering the nucleus, causing a series of reactions, such as an increase in
reactive oxygen species and a decrease in the mitochondrial membrane potential, thereby leading to cell apoptosis. In summary,
IRMOF-10 is an excellent
drug carrier and CUR@IRMOF-10 is an effective anti-
liver cancer sustained-release preparation.